Tenderwize
Wróć do wyszukiwania

Open House Original Rebate Contracts 2026-05 Alectinib

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 705 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Originale-Rabattverträge 2026-05 Alectinib

60/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

30 / 100

Czynniki ryzyka

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No estimated contract value or framework maximum is provided. Without this, it is impossible to assess the financial at...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclusion of pharmaceutical rebate contracts (Rabattverträge) for the active substance Alectinib
  • Non-exclusive, open to all eligible pharmaceutical entrepreneurs
Pokaż pełne podsumowanie

This is an Open-House procedure (not a traditional public procurement) by Techniker Krankenkasse and other German health insurers for rebate contracts (Rabattverträge) under § 130c SGB V for the active substance Alectinib. Any eligible pharmaceutical entrepreneur can join at any time during the contract period (max 24 months starting 01.08.2026, ending 31.07.2028). No estimated value is provided. The procedure is non-exclusive with uniform conditions. Submission is via email or postal mail at any time. The tender documents are available online but were not analyzed. Notably, the procedure is not subject to standard procurement law; disputes go to social courts.

Ryzyka

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No estimated contract value or framework maximum is provided. Without this, it is impossible to assess the financial at...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG
  • Must hold a valid marketing authorization for the medicinal product containing Alectinib
  • Must have seat in Germany, EU, or EEA

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Original Rebate Contracts 2026-05 Alectinib

Conclusion of pharmaceutical rebate contracts for the active substance Alectinib under an Open-House procedure. The contract duration is up to 24 months, starting 01.08.2026, with automatic termination upon patent expiry. Participation is possible throughout the contract period.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2026 - Jul 2028

Kategoria

Pharmaceutical products

Termin

Deadline Jul 30, 2028

Szczegóły zamówienia

Data publikacji
01 Jul 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
455118-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3